Business Information
The group's principal activity is to discover and create small molecule drugs through the integration of chemistry, biology and informatics. The group uses the array discovery platform(R) discovery technologies to invent small molecule drugs. The group has collaborations with eli lilly and company, genpath pharmaceuticals inc, icos corporation, intermune inc, Japan tobacco inc, merck and co inc, pfizer inc and takeda chemical industries limited. The products and processes include the optimer building blocks, lead generation and lead optimization. The group offers its products and services throughout the United States, Europe and Japan.
|
|
Name |
Title
|
Email
|
| Kyle Lefkoff | Chmn. | N/A | | David Snitman | Dir., COO, VP - Business Development | Available | | John Yates | Chief Medical Officer | N/A | | Kevin Koch | Dir., Pres., Chief Scientific Officer | Available | | Michael Carruthers | CFO | N/A |
|
|
Year |
Sales |
Net Income |
| 2006 | 45,003 | (39,614) | | 2005 | 45,506 | (23,244) | | 2004 | 34,831 | (25,966)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
